Literature DB >> 27477080

Gut microbiome and liver disease.

Naga S Betrapally1, Patrick M Gillevet1, Jasmohan S Bajaj2.   

Abstract

Gut microbiota changes are important in determining the occurrence and progression of chronic liver disease related to alcohol, nonalcoholic fatty liver disease, and cirrhosis. Specifically, the systemic inflammation, endotoxemia, and the vasodilation that leads to complications such as spontaneous bacterial peritonitis and hepatic encephalopathy could be related to the gut milieu. Given the poor prognosis of these events, their prevention and early management are essential. Microbiota may be an essential component of the gut milieu that can impact these clinical events, and the study of their composition and function in a culture-independent manner could help understand the prognosis. Recent human and animal studies have shown that the relative abundance and the functional changes of microbiota in the stool, colonic mucosa, and saliva have varying consequences on the presence and prognosis of chronic liver disease and cirrhosis. The impact of therapies on the microbiota is slowly being understood and will likely lead to a more targeted approach to gut microbiota modification in chronic liver disease and cirrhosis. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2016        PMID: 27477080      PMCID: PMC5164947          DOI: 10.1016/j.trsl.2016.07.005

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  130 in total

Review 1.  Host-gut microbiota metabolic interactions.

Authors:  Jeremy K Nicholson; Elaine Holmes; James Kinross; Remy Burcelin; Glenn Gibson; Wei Jia; Sven Pettersson
Journal:  Science       Date:  2012-06-06       Impact factor: 47.728

2.  Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice.

Authors:  Marc-Emmanuel Dumas; Richard H Barton; Ayo Toye; Olivier Cloarec; Christine Blancher; Alice Rothwell; Jane Fearnside; Roger Tatoud; Véronique Blanc; John C Lindon; Steve C Mitchell; Elaine Holmes; Mark I McCarthy; James Scott; Dominique Gauguier; Jeremy K Nicholson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-08       Impact factor: 11.205

3.  Hyperdynamic circulation in patients with cirrhosis: direct measurement of nitric oxide levels in hepatic and portal veins.

Authors:  S Battista; F Bar; G Mengozzi; E Zanon; M Grosso; G Molino
Journal:  J Hepatol       Date:  1997-01       Impact factor: 25.083

4.  Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites.

Authors:  C Guarner; B A Runyon; S Young; M Heck; M Y Sheikh
Journal:  J Hepatol       Date:  1997-06       Impact factor: 25.083

5.  Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis.

Authors:  Vasiliki Arvaniti; Gennaro D'Amico; Giuseppe Fede; Pinelopi Manousou; Emmanuel Tsochatzis; Maria Pleguezuelo; Andrew Kenneth Burroughs
Journal:  Gastroenterology       Date:  2010-06-14       Impact factor: 22.682

6.  Effects of different probiotic strains of Lactobacillus and Bifidobacterium on bacterial translocation and liver injury in an acute liver injury model.

Authors:  D Adawi; S Ahrné; G Molin
Journal:  Int J Food Microbiol       Date:  2001-11-08       Impact factor: 5.277

7.  Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial.

Authors:  J D Grangé; D Roulot; G Pelletier; E A Pariente; J Denis; O Ink; P Blanc; J P Richardet; J P Vinel; F Delisle; D Fischer; A Flahault; X Amiot
Journal:  J Hepatol       Date:  1998-09       Impact factor: 25.083

8.  Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity.

Authors:  Sophie Leclercq; Sébastien Matamoros; Patrice D Cani; Audrey M Neyrinck; François Jamar; Peter Stärkel; Karen Windey; Valentina Tremaroli; Fredrik Bäckhed; Kristin Verbeke; Philippe de Timary; Nathalie M Delzenne
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-06       Impact factor: 11.205

9.  Implication of gut microbiota in nonalcoholic fatty liver disease.

Authors:  Jerome Boursier; Anna Mae Diehl
Journal:  PLoS Pathog       Date:  2015-01-27       Impact factor: 6.823

10.  Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.

Authors:  Jasmohan S Bajaj; Douglas M Heuman; Arun J Sanyal; Phillip B Hylemon; Richard K Sterling; R Todd Stravitz; Michael Fuchs; Jason M Ridlon; Kalyani Daita; Pamela Monteith; Nicole A Noble; Melanie B White; Andmorgan Fisher; Masoumeh Sikaroodi; Huzefa Rangwala; Patrick M Gillevet
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

View more
  36 in total

Review 1.  The gut microbiome: what every gastroenterologist needs to know.

Authors:  Benjamin H Mullish; Mohammed Nabil Quraishi; Jonathan P Segal; Gianluca Ianiro; Tariq H Iqbal
Journal:  Frontline Gastroenterol       Date:  2020-02-04

Review 2.  Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives.

Authors:  Juan P Arab; Marco Arrese; Vijay H Shah
Journal:  Hepatol Res       Date:  2020-01-13       Impact factor: 4.288

3.  Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.

Authors:  Juan P Arab; Rosa M Martin-Mateos; Vijay H Shah
Journal:  Hepatol Int       Date:  2017-05-26       Impact factor: 6.047

Review 4.  A potential role for the gut microbiome in substance use disorders.

Authors:  Katherine R Meckel; Drew D Kiraly
Journal:  Psychopharmacology (Berl)       Date:  2019-04-14       Impact factor: 4.530

Review 5.  Therapies in non-alcoholic steatohepatitis (NASH).

Authors:  Abdul M Oseini; Arun J Sanyal
Journal:  Liver Int       Date:  2017-01       Impact factor: 5.828

6.  Chinese Herbal Medicine for Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.

Authors:  Sihan Peng; Lu Liu; Ziyan Xie; Xiyu Zhang; Chunguang Xie; Sha Ye; Xiangeng Zhang; Xiaoli Liang; Hongyan Wang; Ya Liu
Journal:  Front Pharmacol       Date:  2022-06-27       Impact factor: 5.988

Review 7.  Role of cAMP and phosphodiesterase signaling in liver health and disease.

Authors:  Banrida Wahlang; Craig McClain; Shirish Barve; Leila Gobejishvili
Journal:  Cell Signal       Date:  2018-06-11       Impact factor: 4.315

Review 8.  Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions.

Authors:  Tomas Hrncir; Lucia Hrncirova; Miloslav Kverka; Robert Hromadka; Vladimira Machova; Eva Trckova; Klara Kostovcikova; Pavlina Kralickova; Jan Krejsek; Helena Tlaskalova-Hogenova
Journal:  Microorganisms       Date:  2021-04-29

9.  Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Eleonora Scorletti; Paul R Afolabi; Elizabeth A Miles; Debbie E Smith; Amal Almehmadi; Albandri Alshathry; Caroline E Childs; Stefania Del Fabbro; Josh Bilson; Helen E Moyses; Geraldine F Clough; Jaswinder K Sethi; Janisha Patel; Mark Wright; David J Breen; Charles Peebles; Angela Darekar; Richard Aspinall; Andrew J Fowell; Joanna K Dowman; Valerio Nobili; Giovanni Targher; Nathalie M Delzenne; Laure B Bindels; Philip C Calder; Christopher D Byrne
Journal:  Gastroenterology       Date:  2020-01-25       Impact factor: 33.883

Review 10.  Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction.

Authors:  Cornelius Engelmann; Joan Clària; Gyongyi Szabo; Jaume Bosch; Mauro Bernardi
Journal:  J Hepatol       Date:  2021-07       Impact factor: 30.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.